Comparing two drug combos for elderly myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares two different drug combinations (DRd and VRd-lite) for older adults (65+) who are newly diagnosed with multiple myeloma. The goal is to see which combination works better and is easier to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years old or older.
- You have been newly diagnosed with multiple myeloma and your doctor can measure the myeloma protein in your blood or urine.
- You are expected to live at least 3 more months from now.
- You do not have an active serious infection like hepatitis B or C.
- You do not have severe nerve pain or numbness in your hands or feet before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study compares two drug combinations—chidamide plus VRD versus VRD alone—to see which works better for primary high-risk multiple myeloma. The goal is to improve response while closely monitoring side effects and heart/lung safety.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
This trial tests whether a new drug called elranatamab combined with lenalidomide works better than the standard daratumumab/lenalidomide combination as maintenance therapy after a stem cell transplant for newly diagnosed myeloma.
This trial tests a combination of three drugs (isatuximab, bortezomib, lenalidomide, and a steroid) for people with newly diagnosed multiple myeloma who are older or frail and cannot have a stem cell transplant. It focuses on those with a certain type of myeloma cell in their blood, to see if the treatment works well and is safe.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.